Netherton Syndrome
Conditions
Brief summary
To assess the safety, tolerability, and efficacy of QRX003 lotion (4%) when added to standard of care treatment regimen, including systemic therapy in subjects with Netherton syndrome
Interventions
QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
Sponsors
Quoin Pharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Masking description
Open Label
Intervention model description
Open Label
Eligibility
Sex/Gender
ALL
Age
14 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subject is a male or non-pregnant female at least 14 years of age. * Females must be post-menopausal , surgically sterile , or use an effective method of birth control , for the duration of the study and for 3 months following completion of treatment. Women of childbearing potential (WOCBP) must have a negative urine pregnancy test (UPT) at Visit 1/Screening and Visit 2/Baseline. * Subject has a clinical diagnosis of NS and agrees to genetic testing at Visit 1/Screening for confirmation of NS diagnosis if the subject does not have test results confirming a SPINK5 mutation. * Subject has NS lesions in the Treatment Area (i.e., arms or lower legs). * Subject is in good general health and free of any disease state or physical condition that might impair evaluation of NS or exposes the subject to an unacceptable risk by study participation. * Subject is on a stable treatment regimen including systemic therapy for NS prior to baseline that is expected to remain stable for the duration of the study
Exclusion criteria
* Subject is pregnant, lactating, or is planning to become pregnant during the study. * Subject has any skin pathology in the Treatment Area or condition that, could interfere with the evaluation of the test article or requires use of interfering topical, systemic, or surgical therapy. * Subject has active cancer of any type excluding non-melanoma skin cancer outside of the Treatment Area. * Subject has diabetes of any type, except non-insulin dependent diabetes mellitus that is reasonably controlled. * Subject has evidence of active infection during screening, or serious infection within 30 days prior to Visit 2/Baseline. * Subject has known human immunodeficiency virus, hepatitis B or C virus, or active or latent tuberculosis. * Subject has used ultraviolet phototherapy within the Treatment Area within 4 weeks prior to Visit 2/Baseline. * Subject has used topical prescription treatment in the Treatment Area within 2 weeks prior to Visit 2/Baseline. * Subject has used any topical bland moisturizers/emollients in the Treatment Area within 24 hours prior to Visit 2/Baseline. * Subject is currently enrolled in an investigational drug, biologic, or device study. * Subject has used an investigational drug, biologic, or device treatment within 30 days prior to Visit 2/Baseline.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of subjects with 1-point reduction on IGA | Up to week 16 | Proportion of subjects with 1-point reduction on the Investigator's Global Assessment (IGA) from Baseline. The IGA assesses overall severity of a subject's NS based on a 5-point scale where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. |
| Proportion of subjects with 2-point reduction on IGA | Up to week 16 | Proportion of subjects with 2-point reduction in IGA from Baseline. |
| NS surface area change | Up to week 16 | Change from Baseline in total Body Surface Area (BSA) affected by NS in the Treatment Area |
| WI-NRS score change | Up to week 16 | Change from Baseline in the Worst Itch-Numeric Rating Scale (WI-NRS) score ≥4. Itch severity is graded on an 11-point scale where 0 represents "no itch" and 10 represents "worst itch imaginable". |
| Assessment of subject satisfaction with treatment based on TSQM | Up to week 16 | Assessment of subject satisfaction with treatment based on the Treatment Satisfaction Questionnaire for Medication (TSQM). The TSQM measures a subject's level of satisfaction or dissatisfaction with the treatment. Composite scores can range from 0 to 100; higher scores indicate better satisfaction. |
| Proportion of subjects requiring rescue therapy | Up to week 16 | Proportion of subjects requiring rescue therapy |
| Safety Assessment-AEs | Up to week 16 | Any local and systemic AEs (Adverse Events)/serious AEs |
| Safety Assessment-LSRs | Up to week 16 | Number of subjects with presence of the following LSRs (Local Skin Reactions): edema, excoriations, oozing/vesiculation/crusting, and erosions at any study visit. |
Countries
United States
Contacts
CONTACTTI Clinical Research
CONTACTOleg G Khatsenko
STUDY_DIRECTORTony Andrasfay
Therapeutics, Inc.
Outcome results
None listed